Market capitalization | $2.58m |
Enterprise Value | $1.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.43 |
P/S ratio (TTM) P/S ratio | 0.78 |
P/B ratio (TTM) P/B ratio | 1.02 |
Revenue (TTM) Revenue | $3.29m |
EBIT (operating result TTM) EBIT | $-2.91m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast NanoVibronix, Inc.:
1 Analyst has issued a forecast NanoVibronix, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 3.29 3.29 |
102%
102%
|
|
Gross Profit | 1.96 1.96 |
172%
172%
|
|
EBITDA | -2.91 -2.91 |
50%
50%
|
EBIT (Operating Income) EBIT | -2.91 -2.91 |
50%
50%
|
Net Profit | -3.09 -3.09 |
47%
47%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. It targets wound healing and pain therapy, and can be administered at home, without the assistance of medical professionals. Its products include WoundShield, PainShield, and UroShield. It operates through the following geographical segments: United States, Israel, United Kingdom, European Union, India, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Melville, NY.
Head office | United States |
CEO | Brian Murphy |
Employees | 16 |
Founded | 2003 |
Website | www.nanovibronix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.